文献速递系统性红斑狼疮

西班牙贝利尤单抗治疗系统性红斑狼疮多中心注册研究:日常临床实践数据

Spanish multicenter registry of belimumab in systemic lupus erythematosus: Data from daily clinical practice.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-02

该研究为西班牙44家医院的多中心回顾性观察研究,纳入533例符合EULAR/ACR 2019、SLICC和/或ACR 1997分类标准的SLE患者,描述2011年至2024年5月贝利尤单抗(BLM)在日常临床实践中的使用情况。结果显示BLM治疗与泼尼松剂量、SLEDAI-2K评分及抗dsDNA抗体水平显著下降相关,补体C3和C4升高,并显示可接受的安全性。

要点

  • BLM治疗与泼尼松剂量、SLEDAI-2K评分及抗dsDNA抗体水平显著下降相关。
  • 151例(28.3%)中断治疗,主要因疗效不足(56.7%)和感染(12.1%)。
  • 既往使用bDMARD的患者药物生存期更差(p < 0.001)。

核心结论

  • BLM治疗与SLE疾病活动度和血清学标志物改善相关,并伴随泼尼松剂量减少,安全性可接受。

研究设计与样本

  • 描述性、观察性、回顾性、多中心研究,纳入西班牙44家医院2011年至2024年5月启动BLM治疗的533例SLE患者。

主要发现

  • 随访平均22.6个月(SD: 21.2),泼尼松剂量、SLEDAI-2K评分和抗dsDNA抗体水平显著下降,补体C3和C4升高。
  • 114例患者接受肾活检,IV型和III型肾炎最常见(分别为44.7%和21.2%)。
  • 75%的患者在2017-2024年期间开始治疗,该期间bDMARD、csDMARD和泼尼松使用频率更低,药物持久性高于2011-2016年期间。
  • 151例(28.3%)中断治疗,主要因疗效不足(56.7%)和感染(12.1%)。

关键数值与推荐

  • SLE诊断基于EULAR/ACR 2019、SLICC和/或ACR 1997分类标准。
  • 既往使用bDMARD的患者药物生存期更差(p < 0.001),单药治疗患者无差异(p = 0.06)。

临床怎么用

  • 日常实践中BLM可用于改善SLE疾病活动度和血清学指标,并减少泼尼松用量。
  • 既往使用bDMARD的患者可能需关注药物持久性。

局限性

  • 回顾性观察性设计,可能存在信息偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The monoclonal antibody belimumab (BLM) is the first biologic drug approved for the treatment of systemic lupus erythematosus (SLE). While the efficacy and safety profile of BLM has been well documented in clinical trials, both in SLE in general and in lupus nephritis (LN) in particular, it is necessary to obtain data from daily clinical practice. OBJECTIVES: To describe Spanish experience with BLM for treatment of SLE in daily clinical practice from 2011 until May 2024. METHODS: We performed a descriptive, observational, retrospective, and multicenter study of patients diagnosed with SLE based on the classification criteria of EULAR/ACR 2019, SLICC, and/or ACR 1997 who were starting treatment with BLM. Data were collected from the clinical history at 44 hospitals throughout Spain. The primary objective was to analyze laboratory and clinical data, effectiveness and safety. We also assessed the reduction in use of prednisone (or equivalent) and persistence of treatment. The analyses were performed overall and by differentiating between 2 periods (2011-2016 [period 1] and 2017-2024 [period 2]) and according to the subpopulation of patients with LN. Early BLM initiators, patients in monotherapy (HCQ allowed) and patients with prior biologic disease-modifying antirheumatic drugs (bDMARD) treatment were also analyzed. RESULTS: The registry contains 533 patients (85.7% women, 14.3% men). Mean duration of follow-up was 22.6 months (SD: 21.2). Significant decreases were observed for the dose of prednisone, SLEDAI-2 K score, and anti-dsDNA antibody levels, whereas increases were observed for complement C3 and C4. Kidney biopsy, performed in 114 patients, revealed class IV and class III nephritis to be the most common types (44.7% and 21.2%, respectively). Three-quarters of patients (75%) started treatment in period 2, where the less frequently used drugs were bDMARD, conventional synthetic disease-modifying antirheumatic drugs (csDMARD), and prednisone. In addition, drug persistence was greater than for period 1. Patients treated after bDMARD had a worse survival (p < 0.001) while no differences were observed in patients treated in monotherapy (p = 0.06); in early BLM patients drug survival was similar to those after at least 1 csDMARD (findings were consistent in adjusted multivariable models). A total of 151 patients (28.3%) interrupted treatment, mainly owing to lack of efficacy (56.7%) and infections (12.1%). CONCLUSIONS: We present data on the effectiveness and safety of the largest series to date of SLE patients treated with BLM in daily clinical practice in Spain. Our results show that BLM use was associated with improvements in disease activity and serologic markers, along with prednisone dose reductions, and showed an acceptable safety profile.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Aldasoro V, Laiño M, Enguita M, et al. Spanish multicenter registry of belimumab in systemic lupus erythematosus: Data from daily clinical practice. Semin Arthritis Rheum. 2026. PMID: 42269227. doi:10.1016/j.semarthrit.2026.153004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。